Secular trends in first line treatment with disease modifying antirheumatic drugs in rheumatoid arthritis: An international real‐world study by the OHDSI and EHDEN networks

Oct-20

AUTHORS : Anthony G. Sena, Janssen R&D, Titusville, NJ, USA and Department of Medical Informatics, Erasmus MC, Rotterdam, Netherlands – Email: asena5@its.jnj.com – Profile: https://www.healthdatascience.nl/anthony-sena-cv

JOURNAL : Pharmacoepidemiology and Drug Safety

REFERENCE: 29(S3):245

DOI : 10.1002/pds.5114

Secular trends in first line treatment with disease modifying antirheumatic drugs in rheumatoid arthritis: An international real‐world study by the OHDSI and EHDEN networks

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study